Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF 06835919 · 1 trial · 1 indication
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf)
| Arm | Type | Description |
|---|---|---|
| Sequence 1 | EXPERIMENTAL | midazolam alone followed by combination of PF 06835919 and midazolam |
| Sequence 2 | EXPERIMENTAL | PF 06835919 in combination with midazolam followed by midazolam alone |
| Name | Type | Description |
|---|---|---|
| PF 06835919 | DRUG | 300 mg |
| Midazolam | DRUG | 7.5 mg |
Inclusion Criteria: * Male and female participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiovascular tests. * Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). Exclusion Cri...
PF 06835919 is an investigational small molecule being studied for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), and hepatic impairment. It has been evaluated in healthy volunteers and in patients with NAFLD and type 2 diabetes mellitus. It is not approved and remains in clinical development.
PF 06835919 is a small molecule being developed by Pfizer. Its molecular target has not been disclosed in available clinical trial information. The drug is being studied for metabolic liver conditions including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.
PF 06835919 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. The company has sponsored clinical trials evaluating the drug in healthy volunteers and in patients with non-alcoholic fatty liver disease and related conditions.
PF 06835919 has completed Phase 1 and Phase 2 clinical trials. The most advanced completed study was a Phase 2 trial in participants with non-alcoholic fatty liver disease and type 2 diabetes mellitus. The drug is investigational and has not been approved by regulatory authorities.
PF 06835919 has been studied in four completed clinical trials: NCT02974374, a single ascending dose study in healthy adults; NCT03031119, a multiple ascending dose and drug-drug interaction study; NCT03969719, a Phase 2 study in NAFLD with type 2 diabetes; and NCT04193436, a pharmacokinetic study in hepatic impairment.
Yes, PF 06835919 and PF-06835919 refer to the same investigational drug. Clinical trial records use the hyphenated form PF-06835919, while the drug name is also written without a hyphen as PF 06835919. Both names identify the same Pfizer small molecule.